Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Recruiting · NCT04421560 · Registry updated 2026-02-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, neoplasm, primary central nervous system lymphoma, refractory malignant neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-02-20 | NCT04421560 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| Merck Sharp & Dohme LLC | 650 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Columbia University Medical center | New York | United States | 224 |
| Dana Farber Cancer Institute | Boston | United States | 133 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |